Interleukin-6 fusion toxin

Drug Profile

Interleukin-6 fusion toxin

Alternative Names: IL-6PE4E; Interleukin-6 Pseudomonas exotoxin fusion protein; Sigosix®

Latest Information Update: 01 Mar 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Serono
  • Developer Nonindustrial source
  • Class Antineoplastics; Interleukins
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myeloid leukaemia

Most Recent Events

  • 01 Mar 2000 Discontinued-Preclinical for Myeloid leukaemia in Netherlands (Unknown route)
  • 01 Mar 2000 Discontinued-Preclinical for Myeloid leukaemia in USA (Unknown route)
  • 25 Jan 1999 No-Development-Reported for Myeloid leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top